Digestive Health & Gastroenterology Clinical Trials Update: Week 14, 2026

Published April 3, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

This Phase 3 trial is testing guselkumab, a biologic medicine, in children with moderate to severe Crohn's Disease. If the treatment works well, it may provide a new option to help reduce symptoms and promote healing of the intestines in young patients. The study is recruiting participants worldwide and will assess results after one year of ongoing therapy.

A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis

This study is exploring how well etrasimod, an oral medication, works for adults with moderate to severe ulcerative colitis. A positive outcome could mean a new treatment that improves symptoms and overall quality of life for people with this condition. The trial includes adults aged 18 to 65 who have not taken etrasimod before and will continue for 52 weeks across several countries.

A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

This Phase 2 trial is testing etrasimod in teenagers ages 12 to under 18 with moderate to severe ulcerative colitis. If successful, it may offer a new oral treatment that helps manage symptoms and inflammation in younger patients. The study is active in multiple countries and focuses on the adolescent age group to better understand the drug’s effects in this population.

Jianpi Lishi Jiedu Granules for Prevention of Postoperative Recurrence in Colorectal Advanced Adenomas

This Phase 3 trial is investigating whether Jianpi Lishi Jiedu Granules can prevent the return of advanced colorectal adenomas after surgery in adults. If effective, this treatment might help reduce the chance of these growths coming back and possibly lower the risk of developing colorectal cancer. The study plans to enroll 376 patients aged 18 to 80 and will evaluate outcomes one year after treatment.

Non-invasive Tests for Non-alcoholic Steato-hepatitis

This study is evaluating a new blood test designed to diagnose and monitor non-alcoholic steatohepatitis (NASH) and liver fibrosis without needing invasive procedures. A successful test could provide a simpler and less uncomfortable way for patients with NASH, type 2 diabetes, or obesity to keep track of their liver health. The trial is currently active in Italy and includes adult participants with these conditions.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.